Literature DB >> 11298610

A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura.

G C Newman1, M V Novoa, E M Fodero, M L Lesser, B M Woloski, J B Bussel.   

Abstract

Treatment with 75 microg/kg/d intravenous (i.v.) anti-D was compared with 50 microg/kg/d in a prospective randomized study of 27 RhD-positive, human immunodeficiency virus-negative, adult, acute, non-splenectomized patients with immune thrombocytopenic purpura (ITP) and platelet counts < or = 30 x 109/l. The higher dose resulted in greater median d 1 (43 x 109/l vs. 7.5 x 109/l; P = 0.012) and d 7 (153 x 109/l vs. 64.5 x 109/l; P = 0.001) platelet increases despite no greater haemoglobin decrease. Children with acute ITP receiving 75 microg/kg/d had overnight platelet increases in seven out of nine cases. The duration of effect at the 75 microg/kg/d dose was 46 d vs. 21 d (P = 0.03). Adverse events were mild to moderate and ameliorated with prednisone and acetaminophen premedication.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11298610     DOI: 10.1046/j.1365-2141.2001.02627.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

Review 1.  Pathophysiology and therapeutic options in primary immune thrombocytopenia.

Authors:  Roberto Stasi
Journal:  Blood Transfus       Date:  2010-11-26       Impact factor: 3.443

Review 2.  RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME).

Authors:  Jenny M Despotovic; Michele P Lambert; Jay H Herman; Terry B Gernsheimer; Keith R McCrae; Michael D Tarantino; James B Bussel
Journal:  Transfusion       Date:  2011-10-07       Impact factor: 3.157

3.  Clinical Practice Updates in the Management Of Immune Thrombocytopenia.

Authors:  Ayesha M Khan; Halina Mydra; Ana Nevarez
Journal:  P T       Date:  2017-12

Review 4.  Treatment of immune thrombocytopenic purpura in children : current concepts.

Authors:  Aziza T Shad; Corina E Gonzalez; S G Sandler
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 5.  Immune thrombocytopenia and pregnancy.

Authors:  Srividhya Sankaran; Susan E Robinson
Journal:  Obstet Med       Date:  2011-10-25

6.  Refractory severe immune thrombocytopenia in a twin pregnancy.

Authors:  Patrick Harrington; Catherine Nelson-Piercy; Catherine Williamson; Nichola Cooper; Rachel Kesse-Adu; Susan Robinson
Journal:  Obstet Med       Date:  2017-07-10

7.  Comparison of anti-D immunoglobulin, methylprednisolone, or intravenous immunoglobulin therapy in newly diagnosed pediatric immune thrombocytopenic purpura.

Authors:  Muhittin Celik; Ali Bulbul; Gönül Aydogan; Deniz Tugcu; Emrah Can; Sinan Uslu; Mesut Dursun
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

8.  Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura.

Authors:  Elham Shahgholi; Parvaneh Vosough; Kambiz Sotoudeh; Khadijeh Arjomandi; Shahla Ansari; Soraya Salehi; Mohammad Faranoush; Mohammad Ali Ehsani
Journal:  Indian J Pediatr       Date:  2009-02-04       Impact factor: 1.967

9.  Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia.

Authors:  Eric Cheung; Howard A Liebman
Journal:  Biologics       Date:  2009-07-13

10.  Refractory immune thrombocytopenia successfully treated with high-dose vitamin D supplementation and hydroxychloroquine: two case reports.

Authors:  Barry Bockow; Tamara Bockow Kaplan
Journal:  J Med Case Rep       Date:  2013-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.